Evangelia Charmandari1, Tomoshige Kino, Takamasa Ichijo, George P Chrousos. 1. Division of Endocrinology and Metabolism, Clinical Research Center, Biomedical Research Foundation of the Academy of Athens, 4 Soranou tou Efessiou Street, Athens, Greece. evangelia.charmandari@googlemail.com
Abstract
CONTEXT: Primary generalized glucocorticoid resistance is a rare genetic condition characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. We review the clinical aspects, molecular mechanisms, and implications of this disorder. EVIDENCE ACQUISITION: We conducted a systematic review of the published, peer-reviewed medical literature using MEDLINE (1975 through February 2008) to identify original articles and reviews on this topic. EVIDENCE SYNTHESIS: We have relied on the experience of a number of experts in the field, including our extensive personal experience. CONCLUSIONS: The clinical spectrum of primary generalized glucocorticoid resistance is broad, ranging from asymptomatic to severe cases of hyperandrogenism, fatigue, and/or mineralocorticoid excess. The molecular basis of the condition has been ascribed to mutations in the human glucocorticoid receptor (hGR) gene, which impair glucocorticoid signal transduction and reduce tissue sensitivity to glucocorticoids. A consequent increase in the activity of the hypothalamic-pituitary-adrenal axis compensates for the reduced sensitivity of peripheral tissues to glucocorticoids at the expense of ACTH hypersecretion-related pathology. The study of functional defects of natural hGR mutants enhances our understanding of the molecular mechanisms of hGR action and highlights the importance of integrated cellular and molecular signaling mechanisms for maintaining homeostasis and preserving normal physiology.
CONTEXT: Primary generalized glucocorticoid resistance is a rare genetic condition characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. We review the clinical aspects, molecular mechanisms, and implications of this disorder. EVIDENCE ACQUISITION: We conducted a systematic review of the published, peer-reviewed medical literature using MEDLINE (1975 through February 2008) to identify original articles and reviews on this topic. EVIDENCE SYNTHESIS: We have relied on the experience of a number of experts in the field, including our extensive personal experience. CONCLUSIONS: The clinical spectrum of primary generalized glucocorticoid resistance is broad, ranging from asymptomatic to severe cases of hyperandrogenism, fatigue, and/or mineralocorticoid excess. The molecular basis of the condition has been ascribed to mutations in the humanglucocorticoid receptor (hGR) gene, which impair glucocorticoid signal transduction and reduce tissue sensitivity to glucocorticoids. A consequent increase in the activity of the hypothalamic-pituitary-adrenal axis compensates for the reduced sensitivity of peripheral tissues to glucocorticoids at the expense of ACTH hypersecretion-related pathology. The study of functional defects of natural hGR mutants enhances our understanding of the molecular mechanisms of hGR action and highlights the importance of integrated cellular and molecular signaling mechanisms for maintaining homeostasis and preserving normal physiology.
Authors: Berenice B Mendonca; Maristela V Leite; Margaret de Castro; Tomoshige Kino; Lucila L K Elias; Tania A S Bachega; Ivo J P Arnhold; George P Chrousos; Ana Claudia Latronico Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: N A Huizenga; P de Lange; J W Koper; W W de Herder; R Abs; J H Kasteren; F H de Jong; S W Lamberts Journal: J Clin Endocrinol Metab Date: 2000-05 Impact factor: 5.958
Authors: Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders Journal: Nat Rev Endocrinol Date: 2013-10-01 Impact factor: 43.330
Authors: Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher Journal: Endocr Rev Date: 2009-11-04 Impact factor: 19.871
Authors: Michael L Roberts; Tomoshige Kino; Nicolas C Nicolaides; Darrell E Hurt; Eleni Katsantoni; Amalia Sertedaki; Filadelfia Komianou; Korina Kassiou; George P Chrousos; Evangelia Charmandari Journal: J Clin Endocrinol Metab Date: 2013-02-20 Impact factor: 5.958
Authors: Nicolas C Nicolaides; Michael L Roberts; Tomoshige Kino; Geoffrey Braatvedt; Darrell E Hurt; Eleni Katsantoni; Amalia Sertedaki; George P Chrousos; Evangelia Charmandari Journal: J Clin Endocrinol Metab Date: 2014-01-31 Impact factor: 5.958
Authors: Jérôme Bouligand; Brigitte Delemer; Annie-Claude Hecart; Geri Meduri; Say Viengchareun; Larbi Amazit; Séverine Trabado; Bruno Fève; Anne Guiochon-Mantel; Jacques Young; Marc Lombès Journal: PLoS One Date: 2010-10-22 Impact factor: 3.240